BCGM Wealth Management LLC Invests $1.23 Million in Pfizer Inc. $PFE

BCGM Wealth Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 49,218 shares of the biopharmaceutical company’s stock, valued at approximately $1,226,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sagespring Wealth Partners LLC boosted its stake in shares of Pfizer by 5.1% in the 4th quarter. Sagespring Wealth Partners LLC now owns 64,609 shares of the biopharmaceutical company’s stock valued at $1,609,000 after purchasing an additional 3,106 shares in the last quarter. KFA Private Wealth Group LLC increased its holdings in Pfizer by 45.1% in the fourth quarter. KFA Private Wealth Group LLC now owns 16,270 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 5,055 shares during the period. TrueWealth Advisors LLC increased its stake in shares of Pfizer by 57.8% in the fourth quarter. TrueWealth Advisors LLC now owns 17,093 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 6,263 shares during the period. Everhart Financial Group Inc. raised its holdings in Pfizer by 14.4% during the 4th quarter. Everhart Financial Group Inc. now owns 26,467 shares of the biopharmaceutical company’s stock worth $659,000 after purchasing an additional 3,327 shares during the last quarter. Finally, Avior Wealth Management LLC raised its stake in Pfizer by 39.5% during the fourth quarter. Avior Wealth Management LLC now owns 47,842 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 13,557 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Bank of America decreased their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.14.

Pfizer Stock Down 1.6%

Shares of NYSE PFE opened at $26.98 on Friday. The company has a market cap of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47. The firm’s fifty day moving average is $26.68 and its 200 day moving average is $25.60. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.